TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Rating of “Hold” by Brokerages

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) have been assigned a consensus recommendation of “Hold” from the six ratings firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price target among brokers that have covered the stock in the last year is $6.00.

Several equities research analysts recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of TScan Therapeutics in a report on Tuesday, April 21st. Wedbush boosted their target price on TScan Therapeutics from $4.00 to $5.00 and gave the stock an “outperform” rating in a report on Thursday, March 5th. Finally, Wall Street Zen lowered TScan Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday.

Institutional Investors Weigh In On TScan Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Boothbay Fund Management LLC lifted its holdings in TScan Therapeutics by 50.0% in the 2nd quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock worth $35,000 after purchasing an additional 8,121 shares during the last quarter. Panagora Asset Management Inc. acquired a new position in shares of TScan Therapeutics during the fourth quarter worth approximately $25,000. HRT Financial LP acquired a new position in shares of TScan Therapeutics during the fourth quarter worth approximately $26,000. Voleon Capital Management LP acquired a new position in shares of TScan Therapeutics during the third quarter worth approximately $87,000. Finally, Marshall Wace LLP acquired a new position in shares of TScan Therapeutics during the second quarter worth approximately $78,000. 82.83% of the stock is currently owned by institutional investors and hedge funds.

TScan Therapeutics Stock Up 4.1%

Shares of TScan Therapeutics stock opened at $1.26 on Tuesday. The firm has a market cap of $71.69 million, a price-to-earnings ratio of -1.31 and a beta of 1.06. The company has a debt-to-equity ratio of 0.34, a current ratio of 6.65 and a quick ratio of 8.41. TScan Therapeutics has a 52-week low of $0.88 and a 52-week high of $2.57. The stock has a 50-day simple moving average of $1.11 and a 200-day simple moving average of $1.15.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.22). TScan Therapeutics had a negative return on equity of 91.94% and a negative net margin of 1,360.61%.The business had revenue of $0.98 million during the quarter, compared to analyst estimates of $2.50 million. On average, equities research analysts expect that TScan Therapeutics will post -1.1 earnings per share for the current fiscal year.

Key Headlines Impacting TScan Therapeutics

Here are the key news stories impacting TScan Therapeutics this week:

• Positive Sentiment: HC Wainwright improved its FY2030 EPS estimate for TScan Therapeutics to ($0.07) from ($0.09), suggesting a slightly better long-term earnings trajectory.
• Neutral Sentiment: The analyst left the broader view of TScan’s business still deeply loss-making, with forecasts showing negative EPS through at least FY2030.
• Negative Sentiment: HC Wainwright lowered its 2026, 2027, 2028, and 2029 EPS estimates, including FY2026 to ($0.88) from ($0.76) and FY2027 to ($0.87) from ($0.79), which points to weaker near- and mid-term profitability expectations.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.